Last reviewed · How we verify
Refractory peripheral T-cell lymphoma
Approved treatments
- Ontak · Eisai
- Ontak · Eisai
Ontak works by binding to the interleukin-2 receptor on cancer cells, triggering a toxic response that kills the cells. - Darvias · Solasia Pharma K.K
Darvias works by inhibiting the enzyme glutathione S-transferase pi (GSTP1), which is involved in the cell's detoxification process. - Ontak · The University of Texas Health Science Center at San Antonio
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Refractory peripheral T-cell lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- Refractory peripheral T-cell lymphoma treatment landscape brief
- Refractory peripheral T-cell lymphoma treatment updates RSS
Frequently asked questions about Refractory peripheral T-cell lymphoma
What drugs treat Refractory peripheral T-cell lymphoma?
Tracked treatments include Ontak, Darvias.
What is the treatment for Refractory peripheral T-cell lymphoma?
Standard treatment for Refractory peripheral T-cell lymphoma includes Ontak, Darvias. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Refractory peripheral T-cell lymphoma patent cliff · Refractory peripheral T-cell lymphoma CI report
- Treatment: Ontak · Eisai
- Treatment: Ontak · Eisai
- Treatment: Darvias · Solasia Pharma K.K
- Treatment: Ontak · The University of Texas Health Science Center at San Antonio
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing